Keros Therapeutics, Inc. KROS
We take great care to ensure that the data presented and summarized in this overview for Keros Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KROS
View all-
Black Rock Inc. New York, NY2.51MShares$36.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.96MShares$28.3 Million0.0% of portfolio
-
Braidwell LP Stamford, CT1.89MShares$27.4 Million1.68% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.69MShares$24.4 Million2.53% of portfolio
-
State Street Corp Boston, MA1.2MShares$17.4 Million0.0% of portfolio
-
Holocene Advisors, LP New York, NY1.2MShares$17.3 Million0.07% of portfolio
-
Alkeon Capital Management LLC New York, NY1.1MShares$15.9 Million0.04% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.02MShares$14.7 Million0.44% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT915KShares$13.2 Million0.73% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD910KShares$13.1 Million0.0% of portfolio
Latest Institutional Activity in KROS
Top Purchases
Top Sells
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Transactions at KROS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 09
2025
|
Adar1 Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
934,258
+4.51%
|
$8,408,322
$9.86 P/Share
|
|
Apr 04
2025
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
49,367
+14.04%
|
$0
$0.3 P/Share
|
|
Feb 18
2025
|
Christopher Rovaldi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Feb 18
2025
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
Feb 18
2025
|
Yung H. Chyung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
Aug 13
2024
|
Carl L Gordon Director |
SELL
Open market or private sale
|
Indirect |
250,000
-19.72%
|
$11,000,000
$44.01 P/Share
|
|
Aug 13
2024
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
250,000
-19.72%
|
$11,000,000
$44.01 P/Share
|
|
Nov 04
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-100.0%
|
$1,800,000
$45.29 P/Share
|
|
Nov 04
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$640,000
$16.0 P/Share
|
|
Jun 09
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-71.87%
|
$920,000
$46.25 P/Share
|
|
Jun 09
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$320,000
$16.0 P/Share
|
|
Jun 08
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-93.25%
|
$960,000
$48.16 P/Share
|
|
Jun 08
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$320,000
$16.0 P/Share
|
|
Apr 08
2023
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.56%
|
$0
$0.48 P/Share
|
|
Nov 29
2022
|
Tomer Kariv |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Nov 29
2022
|
Ran Nussbaum |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Nov 29
2022
|
Pontifax Management 4 G.P. (2015) Ltd. > 10% Shareholder |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Jul 15
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
46,034
-32.62%
|
$1,381,020
$30.0 P/Share
|
|
Jul 15
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,034
+24.6%
|
$0
$0.3 P/Share
|
|
Jul 13
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,916
-1.97%
|
$57,480
$30.0 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 49.4K shares |
|---|---|
| Grant, award, or other acquisition | 148K shares |
| Open market or private purchase | 934K shares |
| Open market or private sale | 500K shares |
|---|